Abstract
A protocol for a retrospective cohort study and interrupted time series analysis to investigate the effect of successive COVID related “lockdown” restrictions on major trauma presentations and patient outcomes in English hospitals. The study specifically aims to assess: 1) The impact of successive “lockdowns” on the volume, demographics, injury mechanism, severity, treatment and outcomes of major trauma in England. 2) If the implementation of “lockdowns” affected major trauma related mortality.
A patient cohort will be derived from the Trauma and Audit Research Network (TARN) database, for all trauma receiving hospitals in England, between 1st of January 2017 to 1st of September 2021. This period encompasses two national “lockdown” periods (23rd March 2020 to 29th June 2020 and 2nd Nov 2020 to 16th May 2021) in England. A time series will be used to illustrate changes in the volume and mechanism of injury associated with successive “lockdowns”. Demographic characteristics and features of the clinical care pathways will be compared during the “lockdown” and equivalent pre-COVID periods. To specifically assess if there were any changes in risk adjusted mortality associated with the “lockdowns” interrupted time series analysis will be conducted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any direct funding and has been internally commissioned by the Trauma Audit and Research Network (TARN) research committee.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis will be conducted on fully anonymised Trauma Audit and Research Network (TARN) data. The UK Health Research Authority Patient Information Advisory Group (PIAG) has given approval (Section 251) for analysis of anonymised Trauma Audit and Research Network (TARN) data. Details of the Section 251 approval are available here: https://www.tarn.ac.uk/Content.aspx?ca=2&c=3857.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data may be obtained from a third party and are not publicly available. The de-identified patient data used for this study are the property of the Trauma Audit and Research Network (TARN), based at the University of Manchester. These data may be requested directly from TARN.
